What novel therapies are under investigation for the treatment of high-risk MPN?

Current clinical landscape in anemic myelofibrosis

Optimal treatment sequencing in anemic myelofibrosis

Treatment sequencing and ongoing clinical trials in anemic myelofibrosis

Q&A session

How do TP53 mutations impact survival in patients with MPN?

Promising new drugs in MPN therapy

Can ruxolitinib replace hydroxyurea as a frontline therapy for PV?

Thrombotic / hemorrhagic complications

The role of AI in the future of MPN bone marrow histopathology

What are the current treatment options for intermediate/higher risk patients with MF?

What are the management considerations for accelerated- and blast-phase MPN?

Luspatercept for the treatment of patients with anemic myelofibrosis: Q&A session

Luspatercept compared with other available therapies for MF

NCT03194542: Key efficacy and safety findings

NCT03194542 trial: Luspatercept for the treatment of patients with anemic myelofibrosis

Luspatercept mechanism of action

What implications might the PERSIST-2 landmark OS analysis data have on the use of pacritinib in MF?

Should JAK2 VAF testing be implemented as routine in risk assessment and disease monitoring in MPN?

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

New agents in the MF therapeutic landscape

Is transplantation still the only curative treatment for MF?

What are the key considerations in managing pregnancy in MPN?

Ropeginterferon Alfa-2b for the treatment of low-risk patients with polycythemia vera

How to treat cytopenic patients with MPN

Can JAK2V617F VAF variations help predict clinical and survival outcomes?

How can chromosomal and mutation abnormalities in chronic MPN inform clinical decision making?

Which patients with MF could benefit the most from telomerase inhibitors?

What is the rationale for using BET inhibitors to treat myelofibrosis?

How do symptoms inform treatment decisions in MPN?